New Federal Contractors — February 03, 2026

Secured $458M (41% of total) in firm fixed-price construction deals from GSA ($277M) and NIH ($180M), with $144M outlayed signaling execution momentum.

$850M in HHS awards (75% total) across BARDA, CMS, NIH provide multi-year visibility to 2028, with $255M outlayed (30% obligated).

ATI's $304M BARDA award for biological manufacturing highlights federal scale-up in health preparedness, but low $11M outlay and cost-plus fee cap investor upside.

Low initial outlays average 20-30% of obligations (e.g., $11M/$304M for ATI, $21M/$277M for Hensel GSA) signal potential delays.

Firm fixed-price structures on $458M Hensel Phelps contracts expose to construction cost overruns amid 2026-2028 timelines.

Cost-plus fixed-fee on $674M (ATI, Emmes, GD IT) invites audits and fee caps; long durations to 2028 vulnerable to HHS budget shifts.

$192M unexercised options (Emmes $117M, ATI/GD IT ~$75M) plus extensions to 2028 offer 17% upside on $1.13B base.

HHS lab/data/infectious disease focus ($650M) positions contractors for follow-on R&D amid sustained federal priorities.

75% of value ($850M) targets R&D manufacturing, labs, and CMS support, with 60% outlayed on mature awards signaling execution scale.

Full obligations on $458M Hensel Phelps projects provide locked-in backlog through 2028.

{"entity"=>"Hensel Phelps Construction Co.", "reason"=>"41% value capture with $144M outlayed positions for follow-ons.", "trigger"=>"$57M NIH balance outlay or new GSA awards"}

{"entity"=>"HHS Budget Allocations", "reason"=>"Dominates 4/5 contracts; extensions/options hinge on funding.", "trigger"=>"FY2027 appropriations increase >5% for NIAID/CMS/NIH"}

{"entity"=>"THE EMMES COMPANY", "reason"=>"$117M options represent largest upside potential.", "trigger"=>"Option exercise to approach $287M ceiling"}